解聚复肾宁治疗早期2型糖尿病肾病  

Clinical Study of Jieju Fushenning in Treatment of Early Type Ⅱ Diabetic Nephropathy

作　　者：焦颖华[1] 邢磊[1] 田发明[2] 崔立华[2] 王志文[1] 孙尧[1] 李向男[2] 

机构地区：[1]河北联合大学附属医院,河北唐山063000 [2]河北联合大学,河北唐山063000

出　　处：《中国实验方剂学杂志》2013年第23期317-320,共4页Chinese Journal of Experimental Traditional Medical Formulae

基　　金：河北省科技计划项目(112761138)

摘　　要：目的:探讨解聚复肾宁治疗早期糖尿病肾病(DN)的临床疗效。方法:研究对象为我院收治的120例早期2型DN患者,将其随机分为解聚复肾宁组、厄贝沙坦组、解聚复肾宁+厄贝沙坦组、对照组。每组各30例,12周为1疗程,观察各组治疗前后相关指标的变化。结果:解聚复肾宁组治疗后空腹血糖、24 h尿微量白蛋白排泄率、血肌酐、糖化血红蛋白等指标显著好转,血清和尿液中血管紧张素Ⅱ(AngⅡ),结缔组织生长因子(CTGF)均显著降低,解聚复肾宁和厄贝沙坦联合治疗明显优于两类药物单独应用(P<0.05)。结论:解聚复肾宁对早期2型DN疗效确切,可延缓病情进展,提高患者的生活质量,值得临床推广使用。Objective： To investigate the clinical efficacy of Jieju Fushenning（JJFSN） in the treatment of early diabetic nephropathy. Method： One hundred and twenty patients with early type Ⅱ DN admitted to our hospital were randomly divided into JJFSN group,Irbesartan group,JJFSN and Irbesartan group,and control group,each group had 30 patients,with 12 weeks as a treatment course.The changes of relevant indicators before and after treatment were observed. Result： In the JJFSN group,the fasting plasma glucose,urinary albumin excretion rate,serum creatinine,glycosylated hemoglobin A1c and other indicators significantly improved.Blood angiotensinⅡ,blood connective tissue growth factor（CTGF）,urinary angiotensin Ⅱ,urinary CTGF significantly reduced.The combined application of JJFSN with Irbersartan had better clinical effect than that of Irbersartan and JJFSN used respectively（P〈0.05）. Conclusion： Jieju Fushenning is effective in the treatment of early type Ⅱ DN,can delay disease progression and improve patients quality of life,thereby worthy of clinical application.

关 键 词：解聚复肾宁 糖尿病肾病 血管紧张素Ⅱ 结缔组织生长因子 

分 类 号：R587.2[医药卫生—内分泌]